Pay in 4 interest-free payments of $6.25 Learn more
Ships within 48 hours · Estimated delivery Oct 31 - Nov 5
People with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) or with a personal or family history of medullary thyroid carcinoma (MTC) should not use semaglutide
As reported by the American Journal of Managed Care, the approval of an oral semaglutide formulation marked the beginning of what many are calling the oral GLP-1 era. In December 2025, the FDA approved the Wegovy (semaglutide) tablet as the first once-daily oral GLP-1 receptor agonist indicated for chronic weight management in adults with obesity or overweight
Listen below, or check out the show on Apple, YouTube, or Spotify
She was pretty excited about it
Available online at: www.ema.europa.eu/en/news/ema-statement-ongoing-review-glp-1receptor-agonists (Accessed September 1, 2025)
Important safety information: Wegovy (semaglutide) is a prescription-only medication for managing obesity and weight-related conditions
